H3B-6527 is a potent, selective FGFR4 inhibitor developed for FGF19-driven hepatocellular carcinoma research. It demonstrates antineoplastic activity in both in vitro cell-based assays and in vivo xenograft models, making it a key tool for studying targeted HCC therapies.
Molekulargewicht:
629.54
Reinheit:
99.85% (May vary between batches)
CAS Nummer:
[1702259-66-2]
Formel:
C29H34Cl2N8O4
Target-Kategorie:
FGFR
Anwendungsbeschreibung:
Solubility: DMSO:6.3 mg/mL (10.01 mM)
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten